Armistice reports 5.30% stake in Verastem
Verastem, Inc. ownership update: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 3,536,000 shares of common stock, representing 5.30% of the class as of 12/31/2025.
Rhea-AI Filing Summary
Verastem, Inc. ownership update: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 3,536,000 shares of common stock, representing 5.30% of the class as of 12/31/2025. The filing states Armistice Capital exercises shared voting and dispositive power over these shares under its Investment Management Agreement; the Master Fund is the direct holder. The filing is a joint Schedule 13G signed on 02/17/2026.
Positive
- None.
Negative
- None.
Insights
Armistice holds a 5.30% stake (3,536,000 shares) reported as of 12/31/2025.
Armistice Capital is disclosed as the investment manager exercising shared voting and dispositive power over 3,536,000 shares, which the filing labels as 5.30% of common stock. The Master Fund is identified as the direct holder.
Timing: the position is reported as of 12/31/2025 with the joint filing signed 02/17/2026. Subsequent filing updates would show changes in this position.
Filing is a joint Schedule 13G disclosure with standard attribution and disclaimers.
The statement explains that Armistice Capital, as investment manager, may be deemed to beneficially own the securities held by Armistice Capital Master Fund Ltd., while the Master Fund disclaims beneficial ownership due to its inability to vote or dispose under the Investment Management Agreement.
Signatures and a joint filing agreement are included and dated 02/17/2026; this aligns with routine Schedule 13G reporting obligations for institutional investors.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does Armistice Capital report in Verastem (VSTM)?
Who is listed as the reporting persons on the Schedule 13G for VSTM?
When was the Schedule 13G signed and filed?
AI-generated analysis. How Rhea-AI works. Not financial advice.